AML cells with FLT3-ITD or NPM1 mutations are correlated with significantly increased levels of CD123 as compared to AML cells with wild-type FLT3 or NPM1 (Ehninger et al., 2014; Cortes et al., 2018; Cruz et al., 2018). Here, NPM1 is linked to acute myeloid leukemia.